FUL.L Regulatory News (FUL)

18 Dec 2006 12:52

Fulcrum Pharma PLC18 December 2006 For immediate release 18 December 2006 FULCRUM PHARMA PLC ("the Group" or "the Company") ANNUAL GENERAL MEETING Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcingservices company, today held its Annual General Meeting at which all of theresolutions put to shareholders were duly passed. Fulcrum's Chairman, Prof. Sir Charles George, said: "Following our AnnualGeneral Meeting today we are pleased to report that trading is in line withexpectations." For further information, please contact: Fulcrum Pharma PLC Tel: 0870 710 7152Jon Court, Chief Executive Notes for editors About Fulcrum Pharma plc Fulcrum Pharma plc is an independent, drug development company that is the firstto offer global virtual drug development and strategic outsourcing services tothe pharmaceutical industry. The Group has expertise in the design, executionand delivery of drug development programmes and relies on state of the artinformation technology and infrastructure in the supply of its services. Through Fulcrum's services to its clients, the Directors believe that there isthe capacity to deliver products faster and more efficiently to the globalpharmaceutical market. Fulcrum does this by using its skills in the design ofdrug programmes that deliver the necessary information for decision-making andproduct registration. In so doing, Fulcrum works closely with its clients tomeet their strategic R&D goals. Fulcrum Pharma is listed on the Alternative Investment Market of the LondonStock Exchange having successfully floated in March 2000. This information is provided by RNS The company news service from the London Stock Exchange